Dr. Jacob Thomas, MD
Claim this profileUSC Norris Comprehensive Cancer Center
Studies Squamous Cell Carcinoma
Studies Head and Neck Squamous Cell Carcinoma
23 reported clinical trials
33 drugs studied
Area of expertise
1Squamous Cell Carcinoma
Stage IV
Stage III
PD-L1 positive
2Head And Neck Squamous Cell Carcinoma
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Jacob Thomas, MD is currently running
Immunotherapy +/− Targeted Therapy
for Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Recruiting1 award Phase 2
VLS-1488
for Advanced Cancer
This trial tests VLS-1488, a new drug for advanced cancers, to find the safest and most effective dose. It targets patients needing new treatment options and checks how the drug interacts with other medications and food.
Recruiting1 award Phase 1 & 26 criteria
More about Jacob Thomas, MD
Clinical Trial Related1 year of experience running clinical trials · Led 23 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jacob Thomas, MD has experience with
- Nivolumab
- PD-1 Inhibitor
- PEOX-based Polymer Encapsulated Paclitaxel FID-007
- Tumor Resection
- Ipatasertib
- Pembrolizumab
Breakdown of trials Jacob Thomas, MD has run
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Solid Tumors
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jacob Thomas, MD specialize in?
Jacob Thomas, MD focuses on Squamous Cell Carcinoma and Head and Neck Squamous Cell Carcinoma. In particular, much of their work with Squamous Cell Carcinoma has involved Stage IV patients, or patients who are Stage III.
Is Jacob Thomas, MD currently recruiting for clinical trials?
Yes, Jacob Thomas, MD is currently recruiting for 5 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Jacob Thomas, MD has studied deeply?
Yes, Jacob Thomas, MD has studied treatments such as Nivolumab, PD-1 inhibitor, PEOX-based Polymer Encapsulated Paclitaxel FID-007.
What is the best way to schedule an appointment with Jacob Thomas, MD?
Apply for one of the trials that Jacob Thomas, MD is conducting.
What is the office address of Jacob Thomas, MD?
The office of Jacob Thomas, MD is located at: USC Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States. This is the address for their practice at the USC Norris Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.